Publications | Flatiron Health | Bladder cancer

Browse every publication tagged Bladder cancer

February 2026
Opportunities for precision oncology: Real-world patterns and disparities in FGFR3 testing among US patients with locally advanced/metastatic urothelial cancer
- Bladder cancer
February 2026
Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (rwOS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) with frailty or comorbidities
- Bladder cancer
- Treatment and Testing patterns
May 2025
Management and outcomes of rash, peripheral neuropathy, and hyperglycemia during first-line treatment of locally advanced/metastatic urothelial cancer in a real-world setting
- Bladder cancer
February 2025
Retrospective, observational analysis of real-world safety outcomes in sacituzumab govitecan-treated patients with locally advanced/metastatic urothelial cancer
- Bladder cancer
February 2025
Real-world safety of first-line therapies for locally advanced or metastatic urothelial cancer in the US
- Bladder cancer
April 2023
Uptake of maintenance immunotherapy and changes in upstream treatment selection among patients with urothelial cancer
- Bladder cancer
- Treatment and Testing patterns
October 2022
Systemic anticancer therapy at the end of life—changes in usage pattern in the immunotherapy era
August 2021
Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy
- Comparative effectiveness
- Bladder cancer
February 2020
Real-world outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving taxane monotherapy following platinum and anti-PD-1/L1 therapy
- Unmet need
- Bladder cancer